DOMINIQUE COSTANTINI

About DOMINIQUE COSTANTINI

Dominique Costantini is a leading French biotechnology executive, best known for her long-standing role at OSE Immunotherapeutics in the fields of immunotherapy and immuno-oncology. She co-founded OSE Immunotherapeutics in April 2012 and served as Chief Executive Officer from 2012 to April 2018. She then became Chairwoman of the Board of Directors from April 2018 to June 2024, before later serving as Director of Development and Strategy. In December 2024, OSE announced that she would retire by the end of that year. Her career at OSE was central to building the company, financing it, and guiding its evolution from an early-stage biotech into a publicly listed company with a clinical and strategic footprint. Before founding OSE, Costantini had built a strong scientific background in life sciences. Available sources note that she conducted research activities at CNRS, INSERM, and the Institut de Transplantation-Urologie-Néphrologie, giving her a solid foundation in biomedical research and translational development. She is also identified as the founder and former CEO of OSE Pharma, the predecessor company created in 2012 to develop innovative cancer immunotherapies. This scientific and entrepreneurial trajectory helped shape her reputation as a biotech builder with deep domain expertise. At OSE Immunotherapeutics, she played a decisive role in private fundraising, the company’s IPO, and the advancement of its clinical portfolio, especially in oncology and inflammatory or autoimmune diseases. Company communications emphasize her contribution to corporate strategy, portfolio development, and scientific positioning. Her leadership style is associated with long-term governance, strong scientific credibility, and a disciplined approach to value creation in a high-risk, innovation-driven environment. Overall, Dominique Costantini stands out as a rare combination of scientist, entrepreneur, and listed-company executive in the French biotech ecosystem.